# A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements

> **NCT02152384** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 28 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin Peglispro
- **DRUG:** Insulin Lispro
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT02152384
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02152384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02152384, "A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02152384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*